Compare Ascendis Pharma A/S (ASND) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Wayfair Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Wayfair Inc trades at $89.25 (market cap $11.78B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Wayfair Inc nearer its low. Which is the better fit depends on your goals.
| ASND | W | |
|---|---|---|
Market Cap | $17.74B | $11.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $119.05 |
52-Week Low | $163.32 | $53.37 |
Enterprise Value | $18.11B | $14.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Wayfair (W) trades at $89.23, down 1.18% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $92.64. The company shows revenue growth to $12.46 billion in 2025 but remains unprofitable with a net loss of $313 million. Recent earnings beat expectations in Q3 and Q4 2025, while Q1 2026 matched estimates. Wayfair is expanding into brick-and-mortar stores and leveraging AI, as highlighted in recent Bloomberg coverage.
The stock presents a mixed outlook: analyst sentiment is positive with 52% buy ratings, but profitability challenges and high debt-to-asset ratio of 95% pose risks. Near-term catalysts include Q2 2026 earnings on August 4, 2026, and store expansion initiatives. Investors should weigh growth potential against persistent losses and competitive pressures in the retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
